The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study

Journal of Thoracic and Cardiovascular Surgery

Volumn 148, Issue 5, 2014, Pages 2280-2286

  Kandioler, Daniela ^a   Schoppmann, Sebastian F ^a   Zwrtek, Ronald ^b   Kappel, Sonja ^a   Wolf, Brigitte ^a   Mittlböck, Martina ^a   Kührer, Irene ^a   Hejna, Michael ^a   Pluschnig, Ursula ^a   Ba Ssalamah, Ahmed ^a   Wrba, Fritz ^a   Zacherl, Johannes ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Landesklinikum Sankt Poelten   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN P53; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; TUMOR BIOPSY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; AUSTRIA; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPARATIVE STUDY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84911004896     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2014.06.079     Document Type: Article

References (30)

1. K.M. Sjoquist, B.H. Burmeister, B.M. Smithers, J.R. Zalcberg, Simes Rj, and A. Barbour Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis Lancet Oncol 12 2011 681 692
2. J.M. Donahue, F.C. Nichols, Z. Li, D.A. Schomas, M.S. Allen, and S.D. Cassivi Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival Ann Thorac Surg 87 2009 392 398 discussion 98-9
3. D. Vallbohmer, A.H. Holscher, S. DeMeester, T. DeMeester, J. Salo, and J. Peters A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer Ann Surg 252 2010 744 749
4. F. Lordick Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography Recent Results Cancer Res 196 2012 201 211
5. M. Weller Predicting response to cancer chemotherapy: the role of p53 Cell Tissue Res 292 1998 435 445
6. A. Petitjean, E. Mathe, S. Kato, C. Ishioka, S.V. Tavtigian, and P. Hainaut Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database Hum Mutat 28 2007 622 629
7. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial Lancet 359 2002 1727 1733
8. J.T. den Dunnen, and S.E. Antonarakis Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion Hum Mutat 15 2000 7 12
9. D.P. Kelsen, R. Ginsberg, T.F. Pajak, D.G. Sheahan, L. Gunderson, and J. Mortimer Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N Engl J Med 339 1998 1979 1984
10. S.S. Zhang, Q.Y. Huang, H. Yang, X. Xie, K.J. Luo, and J. Wen Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis Ann Surg Oncol 20 2013 2419 2427
11. T. Arsenijevic, M. Micev, V. Nikolic, D. Gavrilovic, S. Radulovic, and P. Pesko Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer? J BUON 17 2012 706 711
12. E. Ressiot, L. Dahan, A. Liprandi, R. Giorgi, X.B. Djuorno, and L. Padovani Predictive factors of the response to chemoradiotherapy in esophageal cancer Gastroenterol Clin Biol 32 2008 567 577
13. T. Makino, M. Yamasaki, H. Miyata, S. Yosioka, S. Takiguchi, and Y. Fujiwara p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer Ann Surg Oncol 17 2010 804 811
14. M. Yamasaki, H. Miyata, Y. Fujiwara, S. Takiguchi, K. Nakajima, and T. Nishida p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus Ann Surg Oncol 17 2010 634 642
15. K. Madani, R. Zhao, H.J. Lim, and A.G. Casson Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study Eur J Cardiothorac Surg 37 2010 1427 1432
16. P. Flamen, A. Lerut, E. Van Cutsem, J.P. Cambler, A. Maes, and W. De Wever The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer J Thorac Cardiovasc Surg 120 2000 1085 1092
17. Y. Liu, S. Litiere, E.G. de Vries, D. Sargent, L. Shankar, and J. Bogaerts The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community Eur J Cancer 50 2014 260 266
18. A.G. Sacher, L.W. Le, and N.B. Leighl Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping J Clin Oncol 3 2014 1407 1411
19. L.M. Ellis, D.S. Bernstein, E.E. Voest, J.D. Berlin, D. Sargent, and P. Cortazar American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes J Clin Oncol 32 2014 1277 1280
20. R. Pazdur Endpoints for assessing drug activity in clinical trials Oncologist 13 Suppl 2 2008 19 21
21. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
22. P. van Hagen, M.C. Hulshof, J.J. van Lanschot, E.W. Steyerberg, M.I. van Berge Henegouwen, B.P. Wijnhoven CROSS Group Preoperative chemoradiotherapy for esophageal or junctional cancer N Engl J Med 366 2012 2074 2084
23. D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zöchbauer-Müller, and I. Kührer Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer J Thorac Cardiovasc Surg 135 2008 1036 1041
24. D. Kandioler, R. Zwrtek, C. Ludwig, E. Janschek, M. Ploner, and F. Hofbauer TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer Ann Surg 235 2002 493 498
25. D. Kandioler-Eckersberger, S. Kappel, M. Mittlbock, G. Dekan, C. Ludwig, and E. Janschek The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer J Thorac Cardiovasc Surg 117 1999 744 750
26. D. Kandioler-Eckersberger, C. Ludwig, M. Rudas, S. Kappel, E. Janschek, and C. Wnzel TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin Cancer Res 6 2000 50 56
27. H. Bonnefoi, M. Piccart, J. Bogaerts, L. Mauriac, P. Fumoleau, and E. Brain TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial Lancet Oncol 12 2011 527 539
28. A. Di Leo, M. Tanner, C. Desmedt, M. Paesmans, F. Cardoso, and V. Durbecq p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial Ann Oncol 18 2007 997 1003
29. R. Simon Guidelines for the design of clinical studies for the development and validation of therapeutically relevant biomarkers and biomarker-based classification systems G. Hayes, Biomarkers in breast cancer 2006 Humana Press Totowa 3 15
30. D.J. Sargent, B.A. Conley, C. Allegra, and L. Collette Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2005 2020 2027